Kazakh scientists move to next stage of cancer drug trials
Nazarbayev University (NU) Professor Dos Sarbassov, the developer of the anti-cancer drug, announced the move to a critical new phase of clinical trials in 2026, Qazinform News Agency learnt from the Kazakh Government’s press service.
This phase should prove efficiency against KRAS-mutant tumors, one of the most aggressive and malignant forms of cancer.
Following successful preclinical studies on animals, the homegrown drug received approval for testing with a higher maximum-tolerated dose of the second component in the combination therapy.
The drug will be used before standard chemotherapy. Previously, it was administered after several rounds of standard chemotherapy, when patients were already weakened. The new approach is expected to help observe its impact on tumors and metastases and tolerance to the drug.
Professor Sarbasov emphasized this as a strategic decision to maximize the drug’s potential.
To note, the Kazakh anti-cancer drug has successfully completed the initial stages of testing.
Qazinform News Agency reported, Kazakhstan will register homegrown cancer drug by yearend.
